DIAGNOS to Extend the Exercise Period of Stock Warrants
BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units
BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units initially announced on February 5, 2025 and on February 14, 2025.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.